January 8, 2025 - 07:15

In a recent discussion, Jurrien Timmer, Director of Global Macro, highlighted the ongoing rise in bond yields and its implications for the financial market. Since 2022, the interest rate landscape has undergone a significant reset, prompting a shift in how investors view risk and returns. Timmer emphasized that as bond yields increase, they start to compete with equities, fundamentally altering investment dynamics.
He noted that stocks traditionally offer a premium over what is considered a risk-free asset, but with rising yields, this premium may need to adjust. The long-standing period of suppressed risk premiums appears to be coming to an end, allowing bond yields to rise more substantially. Looking ahead, Timmer suggests that bond yields could potentially surpass the 5% mark by 2025.
However, he cautioned that the lingering effects of inflation, exacerbated by the COVID-19 pandemic, could complicate matters. If the economy accelerates before inflation is fully under control, it could hinder the Federal Reserve's ability to lower interest rates further, leading to a more volatile economic landscape.
May 14, 2026 - 09:23
Energy Transition Bank Financing Struggles to Pull Ahead of Fossil Fuels in AsiaFinancial institutions across Asia are taking uneven steps toward disclosing their climate transition strategies, but the overall picture shows bank financing for clean energy projects has yet to...
May 13, 2026 - 17:53
MNU Student-Athlete Finds Purpose in Friends and FinanceWhen finance major Isaiah Cull first visited MidAmerica Nazarene University, he expected to evaluate basketball programs, academic options and campus life. Instead, he found purpose and...
May 13, 2026 - 03:54
Bain Capital Specialty Finance Q1 Earnings Call HighlightsBain Capital Specialty Finance (NYSE:BCSF) reported first-quarter net investment income that matched its regular dividend, while net income was pressured by unrealized losses tied to select...
May 12, 2026 - 02:54
HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCEHalozyme Therapeutics announced its financial results for the first quarter of 2026 on Tuesday, posting a 42 percent year-over-year increase in total revenue to $377 million. The company also...